Introduction: Ulcerative colitis (UC) provides a well documented premalignant condition in colonic mucosa where carcinogenesis pathways remain poorly understood. Our previous work on apomucin expression in CU suggested the probable involvement of gastric metaplasia on UC malignant transformation. Homeobox genes SOX2 and Pdx-1 are reported as important in the control of gastric apomucins expression. Aim: To evaluated the expression of transcription factors SOX2 and Pdx-1 in colonic mucosa of patients with UC, its relationship with gastric apomucins production and with neoplasia. Material and Methods: Ninety patients with UC were selected. The duration, the extent of disease and the use of therapeutic drugs were registered in all the cases. Colonic mucosa from all the patients was histologically and immunohistochemically assessed by using monoclonal antibodies against the apomucins MUC5AC and MUC6 and the transcription factors SOX2 and Pdx-1. Statistical analysis was performed using Spearmans correlation test (significant p value <0.05). Results: Neoplasia was observed in 16 patients, 8 non-invasive (displasia) and 8 invasive (adenocarcinoma). MUC5AC and MUC6 were detected in 63 and 16 out the 90 cases, 70.0% and 17.8%, respectively. Expression of SOX2 was detected in 20.2% cases and Pdx1 in 74.1%, (both in areas of regenerative mucosa and neoplasia). Correlation between SOX2 and MUC6 (R=0.436, p=0.000) and Pdx-1 and MUC5AC (R=0.562, p=0.000) was observed. SOX2 expression correlated with displasia (R=0.385, p=0.000) and showed a negative correlation with the use of therapeutic agents (R = -0,297, p = 0.007). Pdx-1 correlated with distortion (R=0.324, p=0.003) and inflammation (R = 0,229, p = 0.040). Conclusions: Our study: 1) demonstrates the aberrant expression of gastric transcription factors in UC; 2) supports the involvement of SOX2 and Pdx-1 in the control of the MUC6/MUC5AC production, respectively; 3) suggests the involvement of SOX2 in UC carcinogenic pathway. 
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Introduction: Ulcerative colitis (UC) provides one well documented premalignant condition in the colon. As in other models in the context of chronic inflammation, the presence of metaplastic mucosa may precede the development of dysplasia and invasive neoplasia. Aim: To evaluated the presence of gastric metaplasia in colonic mucosa of patients with UC and its relationship with dysplasia/neoplasia. Material and Methods: Ninety patients with UC were selected. The duration and the extent of disease were registered in all the cases. Biopsies were histologically and immunohistochemically assessed. Crypt distortion, goblet cell depletion, Paneth cell metaplasia and inflammatory activity were graded (absent, mild, moderate, severe), as well as dysplasia and invasive neoplasia (absent or present). Monoclonal antibodies against the gastric apomucins MUC5AC (foveolar) and MUC6 (mucopeptic) were used. Statistical analysis was performed using Spearmans correlation test (significant p value <0.05). Results: Neoplasia was observed in 16 patients, 8 non-invasive (dysplasia) and 8 invasive (adenocarcinoma). MUC5AC and MUC6 were detected in 63 and 16 out the 90 cases, 70,0% and 17,8%, respectively. The staining was patchy for both antibodies, affecting groups of cells more often than isolated cells. The presence of MUC5AC correlated positively with inflammatory activity and goblet cell deplection, (R=0.231, p=0.03 and R=0.211, p=0.048, respectively). The expression of MUC6 correlated positively with age (R=.297, p=0.005), duration of disease (R=0.287, p=0.008), extent of disease (R=0.342, p=0.001), crypt distortion (R=0.276,p=0.01) and the presence of neoplasia (R=0.483, p<0.00). There was no correlation between Paneth cell metaplasia and apomucin expression. Conclusion: Our study demonstrates the aberrant expression of gastric apomucins in UC and suggests that MUC5AC is associated with inflammation while MUC6 is related to the presence of neoplasia. The demonstration of metaplastic cell lineages preceding dysplasia supports the biological link between inflammation and neoplasia, MUC6 emerging as a putative biomarker in UC patients. CRC incidence is increased in ulcerative colitis (UC) and Crohn' s disease (CD). Several differences were reported in the carcinogenesis of IBD-associated CRC (I-CRC) compared to sporadic CRC (S-CRC): e.g. whereas p53 mutations occur early in I-CRC, they appear late in S-CRC. Additionally, in S-CRC, Cdx2 expression (a homeotic gene with anti-oncogenic properties) is decreased, possibly resulting of an inhibitory beta-catenin-SOX9-dependent pathway. Our objectives were to confirm p53 accumulation, and to investigate Cdx2 and beta-catenin expression in I-CRC compared to S-CRC. We investigate p53, Cdx2, and beta-catenin expression by immunohistochemistry in 10 normal and 10 S-CRC colonic mucosal specimens, as well as in IBD specimens without any dysplasia or CRC (CD: n=10, UC: n=10), and I-CRC (CD: n=10, UC: n=10). In I-CRC, p53 was strongly and homogeneously expressed compared to non-inflamed, non-dysplastic, non-CRC IBD, occurs early, and was not related to CRC differentiation. In the normal colonic mucosa, Cdx2 localisation was restricted to the nucleus but its expression becomes fainter in the nucleus and diffuse in the cytoplasm of most S-CRC. However, it remains strongly expressed in the nucleus both in non-dysplasic, non-CRC IBD mucosa, and in I-CRC. In I-CRC, beta-catenin remains localized in the cell membrane, contrasting with beta-catenin translocation into the cytoplasm and nucleus in S-CRC. In conclusion, this data strengthen the idea that carcinogenesis significantly differ between S-CRC and I-CRC. As S-CRC are associated to early alterations in the Wnt/beta-catenin pathway, but less frequently to p53 mutations, I-CRC is early associated to p53 mutations, but not to Cdx2 or betacatenin alterations. In addition to information on differential fundamental mechanisms between S-CRC and I-CRC carcinogenesis, these data may have important implications for future prophylactic and curative therapeutic developments.
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